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932L ower extremity peripheral arterydisease (LE-PAD) is a manifestationof systemic atherosclerotic disease,
which affects over 8 million Americans (1)
and conveys a signiﬁcant health burden
globally (1–3). Although LE-PAD can be
asymptomatic and subclinical, it is associ-
ated with a reduction in functional capacity
and quality of life when symptomatic, and,in its most severe form, is a major cause of limb
amputation (1–3). Patients with LE-PAD are at an
increased risk for myocardial infarction (MI), stroke,
and death (1–5). Given this substantial health burden,
LE-PAD is the focus of a number of evolving medical,
endovascular, and surgical therapies aimed at im-
proving the limb manifestations of the disease. This
proliferation of revascularization devices and thera-
pies has highlighted the need for studies that eluci-
date the direct mechanistic effect, the impact on
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Systematic safety and effectiveness evaluations of
the clinical utility of LE-PAD revascularization ther-
apies and devices (4,6) require high-quality clinical
trials data, both for regulatory approval and for the
development of best practice guidelines to inform
clinical decisions in patients with LE-PAD. Currently,
1 of the biggest barriers to accrual of knowledge in
and across peripheral artery disease (PAD) therapies
and technologies is the lack of consistent deﬁnitions
and nomenclature between clinical trials. Although
validated, standardized deﬁnitions exist for coronary
artery disease endpoints for clinical trials, signiﬁcant
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933the lack of and the need for consistent consensus
deﬁnitions for clinical descriptors, anatomy, surro-
gate measures, and clinical outcomes as new thera-
pies move into clinical practice. Although these
groups have previously proposed standardized deﬁ-
nitions in speciﬁc PAD populations (7–9), these efforts
are recent and await broad application to support
existing clinical trials or ongoing registries in LE-PAD
patients. Unique needs remain for regulatory evalua-
tion and pivotal trials that can support critical trial
processes, such as independent event adjudication,
core laboratory analysis, and safety monitoring. The
value of consensus deﬁnitions across stakeholders for
such device evaluation is the basis for the Peripheral
Academic Research Consortium (PARC) (10).
In response to the need for public access to
consistent deﬁnitions for pharmacologic and device
trials treating patients with LE-PAD, we initiated the
PARC, convening 2 face-to-face meetings on February
2, 2012 and February 1, 2013, at the U.S. Food and
Drug Administration (FDA) headquarters in White
Oak, Maryland, along with numerous interim tele-
conferences and communications. The meetings and
processes were modeled after the previous Academic
Research Consortium (ARC) meetings in 2006, which
aimed to develop standardized deﬁnitions for coro-
nary stent clinical trials (11), and subsequent efforts
aimed at bleeding (Bleeding Academic Research
Consortium [BARC]) (12), and transcatheter aortic
valve implantation (Valve Academic Research Con-
sortium [VARC]) (13,14). The express purpose of the
PARC effort was to develop pragmatic consensus
deﬁnitions to be consistently applied in clinical trials
of patients with LE-PAD. Unique to PARC was the
inclusion of representatives from academia, regula-
tory bodies (from both Japan and the United States),
and industry.
CHALLENGES AND SCOPE OF
STANDARDIZED LE-PAD DEFINITIONS
There were many fundamental challenges in creating
broadly accepted, pragmatic LE-PAD deﬁnitions,
establishing in part the basis for the process and the
scope of the consensus deﬁnitions provided. A central
challenge was the scope of topics requiring deﬁni-
tions. Several prior efforts had evaluated segments of
the LE-PAD population. The foundational document is
the 2012 American College of Cardiology Foundation/
American Heart Association Key Data Elements and
Deﬁnitions of Atherosclerotic Vascular Disease (9), to
which the PARC document has integrated several
characteristics particular to clinical trials in PAD
(15). Other groups involved in nomenclature anddata elements that inﬂuenced PARC include: the
DEFINE group, evaluating deﬁnitions in patients
undergoing lower-extremity endovascular revas-
cularization (7); a vascular surgical group evaluating
objective performance goals and trial design for pa-
tients undergoing endovascular treatment for critical
limb ischemia (CLI) (8); the proceedings from the
Society of Interventional Radiology conference on
critical limb ischemia trials and registries; the Inter-
Society Consensus for Management of PAD (TASC)
(16); and the FDA Clinical Data Interchange Standards
Consortium (CDISC) effort to improve the quality and
efﬁciency of cardiovascular trials. These documents
provided the foundation and nomenclature for much
of the work done by the PARC group. To best integrate
such efforts and construct the most pragmatic and
genuine consensus in its approach, the PARC initia-
tive actively involved as many representative groups
as possible, and reviewed all available “standard”
deﬁnitions from previous sources.
Additionally, patients with LE-PAD span a clinical
spectrum ranging from asymptomatic patients to
those with atypical leg symptoms, typical claudication
with variable degrees of limitation, or CLI including
both rest pain and tissue loss. Across this clinical
spectrum, deﬁnitions for patients were required that
included the accurate elucidation of symptoms,
anatomic characterization of disease, deﬁnitions for
both clinical and imaging short- and long-term mea-
sures, and ﬁnally, clinical outcomes. In addition to
developing deﬁnitions applicable across the wide
spectrum of PAD syndromes, the deﬁnitions would
need to be pertinent to existing and developing ther-
apies and procedures for LE-PAD. A pre-meeting sur-
vey of all participants established key priorities for the
consortium. On the bases of a survey and in-person
think tank meetings, the PARC key priorities for def-
initions included: 1) clinical syndromes; 2) anatomic
considerations; 3) surrogate endpoints including
physiologic and imaging measures; 4) symptomatic
limb endpoints; and 5) other clinical endpoints.
PARC COMPOSITION AND GOALS
As summarized in the ARC charter, the ARC was
founded as an informal collaboration including aca-
demic research organizations from the United States
and Europe, joined by representatives from the FDA
and device manufacturers. The initial ARC work
product was the development of pragmatic consensus
deﬁnitions for coronary stent trials (11). Regulatory
authorities, manufacturers, and professional societies
have universally endorsed the ARC deﬁnition for stent
thrombosis. This initial ARC effort concomitantly
TABLE 1 Clinical Symptom Classiﬁcation
Fontaine Classiﬁcation
4 Proposed PARC Universal Data Elements 4
Rutherford Classiﬁcation
Stage Symptoms Grade Category Symptoms
I Asymptomatic Asymptomatic 0 0 Asymptomatic
II Intermittent claudication/other
exertional limb symptoms
Mild claudication/limb symptoms
(no limitation in walking)
4 0
1
1
2
Mild claudication
Moderate claudicationIIa 4 Moderate claudication/ limb symptoms
(able to walk without stopping >2
blocks or 200 m or 4 min)
IIb Severe claudication/limb symptoms
(only able to walk without stopping
<2 blocks or 200 m or 4 min)
4 1 3 Severe claudication
III Ischemic rest pain 4 Ischemic rest pain (pain in the distal
limb at rest felt to be due to limited
arterial perfusion)
4 II 4 Ischemic rest pain
IV Ulceration or gangrene 4 Ischemic ulcers on distal leg 4 III 5 Ischemic ulceration
Ischemic gangrene 4 III 6 Ischemic gangrene
4 ¼ comparable terms.
TABLE 2 Hemodynamic Deﬁnitions for CLI
Patients With Tissue Loss Patients With Ischemic Rest Pain
Ankle pressure <70 mm Hg Ankle pressure <50 mm Hg
Toe pressure <50 mm Hg Toe pressure <30 mm Hg
TcPO2 <40 mm Hg TcPO2 <20 mm Hg
Skin perfusion
pressure <40 mm Hg
Skin perfusion
pressure <30 mm Hg (23)
The PARC group provided hemodynamic support for the deﬁnition of CLI. Atypical
leg symptoms are symptoms that are worsened by exertion, but that do not meet
the classic deﬁnition of intermittent claudication. These patients should have
objective/conﬁrmed evidence of PAD by noninvasive testing.
CLI ¼ critical limb ischemia; PAD ¼ peripheral arterial disease; PARC ¼ Periph-
eral Academic Research Consortium; TcPO2 ¼ transcutaneous oxygen pressure.
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934developed a process that was comprehensive and
efﬁcient through the broad inclusion of all relevant
stakeholders. The value of pragmatic consensus deﬁ-
nitions has subsequently been illustrated by the use of
the ARC stent thrombosis deﬁnition in more than 100
clinical trials involvingmore than a dozen drug-eluting
stent platforms, providing the basis for the ongoing
accrual of knowledge about this rare, but catastrophic,
safety concern for drug-eluting stent implants (17–20).
The ARC process relied upon a transparent, noncom-
petitive approach to developing endpoint deﬁnitions
capable of being applied to a wide variety of trial de-
signs or speciﬁc devices. A key principle in ARC efforts
is that the development of a consensus, in particular
endpoint deﬁnitions, is ultimately independent of
how such deﬁnitions are actually applied in any spe-
ciﬁc clinical trial. The PARC group was formed in
keeping with the ARC process and included: repre-
sentatives from academic research groups from the
United States, Japan, and Europe; representatives
from vascular medicine, vascular surgery, interven-
tional radiology, and cardiology; industry representa-
tives; the FDA; and the Pharmaceuticals and Medical
Devices Agency regulatory authorities from Japan
(Online Appendix). The goal of the PARC group was to
develop standardized deﬁnitions for patients with LE-
PAD allowing for clinical characterization and evalua-
tion of therapies on the basis of either imaging or
clinical outcomes. The approach was to have sub-
groups of the overall committee review speciﬁc end-
points and outcomes as writing groups, with review by
thewhole group and adoption of ﬁnal deﬁnitions using
a consensus process.
PARC DEFINIT IONS. C l i n i ca l s ymptoms and
syndromes deﬁn i t i on s . Traditionally, both the
Fontaine and the Rutherford classiﬁcation systemshave been used to capture information regarding
lower extremity symptoms and broadly deﬁned
functional limitations of patients with LE-PAD
(1,3,21,22). The PARC group established baseline
symptom deﬁnitions benchmarked to the established
deﬁnitional schemes. Tables 1 and 2 provide the
Fontaine and Rutherford limb symptom classiﬁca-
tions and the data elements recommended by the
PARC group for capture. It should be noted that PARC
consensus was to deﬁne patients with atypical
symptoms related to PAD as “other exertional leg
discomfort associated with physical limitations from
PAD.” It is assumed that these patients would have
symptoms associated with exertion that would be
atypical in nature, that is, either present at rest with
worsening during exertion or with signiﬁcant time to
symptom resolution. Symptom-limited walking dis-
tance and degree of functional limitation should be
ascertained and captured in these patients, along
with hemodynamic evidence of PAD. The Fontaine
and Rutherford classiﬁcations were modiﬁed to use
descriptive, rather than numeric terms to classify the
severity of PAD limb symptoms. If validated, this
TABLE 3 PARC Lesion and Vessel Characteristics and Deﬁnitions
Lesion or Vessel Term Deﬁnition
Signiﬁcant
peripheral
artery stenosis*
Mild <50%
Moderate 50%–69%
Severe 70%–99%
Occluded 100%
Lesion length Focal #1 cm
Short >1 and <5 cm
Intermediate $5 and <15 cm
Long $15 cm
Degree of lesion
calciﬁcation
(34,26)
Focal <180 (1 side of vessel) and less than one-half of the
total lesion length
Mild <180 and greater than one-half of the total lesion
length
Moderate $180 (both sides of vessel at same location) and less
than one-half of the total lesion length
Severe >180 (both sides of the vessel at the same location)
and greater than one-half of the total lesion length
Anatomic level
of LE-PAD
Aortoiliac Aortoiliac (distal limit bottom of pelvic rim in the AP
view by angiography or inguinal ligament)
Femoropopliteal Femoropopliteal (distal limit is origin of anterior tibial
artery)
Tibialpedal Tibialpedal (anterior tibial and below including foot
arteries)
Aortoiliac
segment
Infrarenal abdominal aorta
Common iliac artery
Internal iliac artery
External iliac artery
Femoropopliteal Common femoral artery
Profunda femoris artery
Superﬁcial femoral artery
P1 segment (above knee popliteal artery): from
Hunter’s canal to proximal edge of patella
P2 segment: from the proximal part of patella to
center of knee joint space
P3 segment (below knee popliteal artery): from the center
of knee joint space to origin of anterior tibial artery
Tibialpedal Tibial-peroneal trunk (from the origin of the anterior
tibial artery to the bifurcation of the posterior
tibial and peroneal artery)
Anterior tibial artery
Posterior tibial artery
Peroneal artery
Plantar pedal loop
pedal vessel
PT, DP†‡
Target lesion Any vascular segment treated or attempted to be treated during the trial
procedure with the index device. The target lesion is the treated
segment including 10 mm proximal and ending 10 mm distal to the
index device or therapy (stent, balloon, or atherectomy catheter).
TLR TLR is any repeat interventionof the target lesions (plus 10mmproximal and
distal to the indexdevice) or surgical bypassof the target vessel performed
for restenosis or other complication involving the target lesion. If the
target vessel is occluded and bypass is done to another artery below the
knee, this should be considered TLR. In the assessment of TLR, angiograms
should be assessed by an angiographic core laboratory (if designated)
and made available to the clinical endpoints committee for review.
Target vessel Any vessel (e.g., noncardiac or nonintracranial) that contains the target
lesion treated with the study device. The target vessel includes the
target lesion as well as the entire length of native vessel upstream and
downstream from the target lesion, including side branches.
Target limb Any symptomatic limb that contains the target lesion and all vessels from
aortic bifurcation to the foot.
The majority of the anatomic classiﬁcations were adapted from Diehm et al. (7). *Lesion stenoses are clinically
based on visual angiographic assessments. For clinical trials, lesion stenosis may be evaluated with core-
laboratory QCA. †PARC recommends continued efforts to encourage documentation of pedal anatomy in rele-
vant patients. ‡It is desirable to obtain selective tibial imaging evaluating the vascular supply to tissue at risk with
categorization of pedal/arcuate vessels in patients with tissue loss.
DP ¼ dorsalis pedis artery; PT ¼ posterior tibial artery; QCA ¼ quantitative coronary angiography; TLR ¼ target
lesion revascularization; other abbreviations as in Table 2.
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935lexicon will clarify ambiguity when reporting baseline
characteristics and outcomes regarding the clinical
stage or change in stage of the patients evaluated.
The PARC group clearly identiﬁed the signiﬁcant
limitations of the current Rutherford classiﬁcation
system in comparing patients with CLI across clin-
ical trials. In part, this was felt to be due to the
changing demographics of CLI patients, with in-
creased rates of diabetes and renal disease. The
Society for Vascular Surgery has proposed a system
for classiﬁcation of patients with threatened limbs
aimed at addressing many of the potential de-
terminants of amputation, including wound extent,
the degree of ischemia and/or perfusion, and pres-
ence and extent of foot infection (wound ischemia
foot infection) (24). This recent approach has not yet
been validated, but represents an area we feel
should be evaluated in CLI trials and considered in
future PARC revisions.
Anatomic ( les ion and vesse l) deﬁni t ions . The
PARC lesion and vessel deﬁnitions are presented in
Table 3. The PARC group reviewed both the DEFINE
group (7) and CDISC anatomic deﬁnitions (25) with
regards to lesion and target lesion endovascular and
surgical revascularization. The deﬁnitions are speciﬁc
for anatomic and lesion characteristics, in contrast to
the TASC anatomic classiﬁcation, which remains
clinically available for guidance about revasculariza-
tion. In deﬁning a “signiﬁcant” anatomic lesion in the
LE-PAD arterial tree, PARC considered options similar
to those evaluated in the coronary circulation,
including classiﬁcation within the 50% to 100% ste-
nosis/occluded group. Given the lack of quantiﬁable
data on the differences in visually estimated stenosis
and outcomes and the difference in size of LE-PAD
vessels, the group recommended an efﬁcient no-
menclature that can be used by clinicians and core
laboratories: mild (<50% diameter stenosis), moder-
ate (50% to 69%), severe (70% to 99%), and occluded
(100%). This system was consistent with prior coro-
nary assessments used per CDISC data element deﬁ-
nitions and LE-PAD proposed imaging surrogate
endpoints during follow-up. Another signiﬁcant
modiﬁcation was the deﬁnition of a treated or target
lesion. Due to the treatment lengths speciﬁc to the LE-
PAD vascular bed, and to ensure coverage for both
efﬁcacy and safety, the deﬁnition of a treated segment
was changed to include 10 mm proximal and distal to
the lesion. Finally, Table 3 also provides a consensus
system for assessing calciﬁcation of LE-PAD vessels.
We recommend DEFINE anatomic groupings
modiﬁed to include aortoiliac, femoropopliteal, and
tibialpedal to deﬁne anatomic locations of disease.
Table 3 presents the segments with their anatomic
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plex lesion and anatomy assessment below the knee
and in the pedal arch, including the angiosome
concept (27,28). The PARC group recommends
continued research and data capture in relevant
patients with distal disease to help inform future ef-
forts. Inherent in the PARC lesion and vessel recom-
mendations is the performance of complete pre- and
post-revascularization imaging to assess the pres-
ence, extent, and location of atherosclerotic disease in
the lower extremity. The PARC group recognizes that
the current classiﬁcation captures lesion stenosis,
location, and some information about morphology,
but does not describe speciﬁc lesion patterns or
features such as aneurysm or ulceration.
Acute procedura l success . To develop a standard-
ized deﬁnition for acute procedural success, the
working group considered both the timing of evalu-
ation and the application of the deﬁnition across a
broad range of possible endovascular and surgical
procedures. Acute procedural success needed to
encompass technical success as well as freedom from
major adverse clinical events. It should be noted for
all procedure success deﬁnitions that the group be-
lieves that, although visual estimation is used for
clinical care, quantitative coronary angiography
would be preferable in clinical trials.TABLE 4 PARC Acute Technical and Procedural Success
Acute Procedu
Deﬁnition of acute procedural success (endovascular and surgical): evidenc
(e.g., death, stroke, myocardial infarction, acute onset of limb ischemia, i
emergent vascular surgery) within 72 h of the index procedure.
Acute Technic
Deﬁnition of acute technical success (endovascular and surgical): evidence
Endovascular
revascularization
Angioplasty alone #50% stenosis
Absence of ﬂow-limiting diss
hemodynamically signiﬁca
Atherectomy alone #50% stenosis
Absence of ﬂow-limiting diss
hemodynamically signiﬁca
Stent or stent graft #30% stenosis
Absence of ﬂow-limiting diss
hemodynamically signiﬁca
Surgical
revascularization
Endarterectomy Patent native vessel on which
was performed
Bypass graft/conduit Patent graft or conduit
Applies to both patients with intermittent claudication/other exertional limb symptoms a
artery to pedal/plantar arteries is recommended to exclude acute adverse events. Two an
technical success. A focused examination of the index limb after sheath removal (endovas
Doppler signals, is also recommended. Deﬁnition of acute procedures success assumes t
failure would also be collected and assessed with regards to timing from the procedure
PARC ¼ Peripheral Academic Research Consortium.Our consensus deﬁnition is:
 Acute technical success for peripheral revascular-
ization is deﬁned as the achievement of a ﬁnal re-
sidual diameter stenosis <30% for stent and <50%
for angioplasty or atherectomy by angiography
at the end of the procedure (and without ﬂow-
limiting arterial dissection or hemodynamically
signiﬁcant translesional pressure gradient <10
mm Hg) for endovascular revascularization or
patent vessel or bypass conduit for surgical revas-
cularization (Table 4) (modiﬁed from the FDA
CDISC deﬁnition).
 Acute procedural success for peripheral revascu-
larization is deﬁned as both acute technical success
and absence of major adverse events (e.g., death,
stroke, MI, acute onset of limb ischemia, index
bypass graft or treated segment thrombosis, and/or
need for urgent/emergent vascular surgery) within
72 h of the index procedure.
This deﬁnition, along with deﬁnitions speciﬁc to
endovascular and surgical procedures, is presented in
Table 4. The group deﬁned urgent surgery as gener-
ally requiring hospitalization and occurring within
24 h of the index procedure and emergency surgery as
needing to be performed without delay. The group
retained conventions from the coronary publishedral Success
e of both acute technical success and absence of major adverse events
ndex bypass graft or treated segment thrombosis, and or need for urgent/
al Success
of successful revascularization as presented in the following text.
ection or
nt translesion gradient
Conﬁrmed by digital subtraction angiography
and/or invasive pressure measurement
demonstrating <10 mm Hg gradient
ection or
nt translesion gradient
Conﬁrmed by digital subtraction angiography
and/or invasive pressure measurement
demonstrating <10 mm Hg gradient
ection or
nt translesion gradient
Conﬁrmed by digital subtraction angiography
and/or invasive pressure measurement
demonstrating <10 mm Hg gradient
operation Conﬁrmed by at least 1 of the following:
 Doppler examination
 Digital subtraction angiography
 Noninvasive hemodynamic measurement
Conﬁrmed by at least 1 of the following:
 Doppler examination
 Digital subtraction angiography
 Noninvasive hemodynamic measurement
nd patients with critical limb ischemia. Completion angiogram from common femoral
giographic, tangential views of the treated segment are recommended to deﬁne acute
cular) and skin closure (surgical), including pulse examination and presence/absence of
hat other previously deﬁned safety endpoints such as major bleeding or acute renal
.
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937studies regarding the time point for evaluation of
successful revascularization utilizing stent technol-
ogy compared with balloon or atherectomy technol-
ogies. Further research on systemic and limb-related
adverse events around revascularization, as well as
long-term clinical outcomes, is needed to inform
these deﬁnitions. The PARC group also felt that spe-
cial emphasis should be paid to ensuring that both
per-protocol and intention-to-treat cohorts were
captured and reported in peripheral revascularization
trials to ensure that all modes of failure are captured.
The PARC group also deﬁned both clinically driven
target vessel revascularization and vessel patency,
adapting relevant coronary deﬁnitions from CDISC.
The deﬁnitions are as follows:
 Clinically driven LE-PAD revascularization is
deﬁned as target lesion revascularization per-
formed due to target lesion diameter stenosis
$50% and either evidence of clinical or functional
ischemia (e.g., recurrent/progressive life-limiting
intermittent claudication, claudication unrespon-
sive to medical therapy, CLI) or recurrence of theTABLE 5 Short- and Long-Term Surrogate Endpoints for Procedural S
Measurement Technique
Subacute
(72 h to 30 days)
I
ABI (or TBI) at rest* Increase in resting ABI or
TBI $0.10 from
pre-procedure value
Resting AB
pre-pro
Failure in f
reduction
0.10 or r
value
Duplex ultrasound† #50% diameter stenosis as deﬁned
by peak systolic velocity index
(ratio of intrastenotic peak
systolic velocity to pre-stenotic
velocity) <2.4
#50% diam
by peak
(ratio o
systolic
velocity
CT/CMR/invasive
angiography
#50% diameter stenosis or #70%
area stenosis
#50% diam
#70%
Ankle (or toe) pressure‡§ >70 mm Hg (Rutherford 4)
>50 mm Hg (Rutherford 5–6)
>70 m
>50 m
kDuplex ultrasound #50% diameter stenosis as deﬁned
by peak systolic velocity index
(ratio of intrastenotic peak systolic
velocity to pre-stenotic
velocity) <2.4
#50%
de
ve
int
ve
ve
CT/MRI/invasive
angiography
#50% diameter stenosis or #70%
area stenosis
#50%
#7
*Patients with ABI $1.4 are considered noncompressible and should not be included in
infrageniculate vessels, and patients with CLI may beneﬁt from evaluation of presence o
event of noncompressible vessels. §Ankle (or toe) pressure used instead of ratio for CL
endovascular and surgical therapy. kThe PARC group did not deﬁne hemodynamic failure
time points for evaluation but recommend that analyses and reports include the entire
ABI ¼ ankle brachial index; CT ¼ computed tomography; CMR ¼ cardiac magnetic resclinical syndrome for which the initial procedure
was performed. Clinically driven target lesion re-
vascularization occurs in the absence of protocol-
directed surveillance ultrasound or angiography.
 Vessel patency includes the absence of clinically
driven target lesion revascularization and/or
recurrent target lesion diameter stenosis $50%
by imaging (e.g., invasive angiography or, most
commonly, duplex ultrasonography). If patency
data are incorporated within the primary endpoint
of a clinical trial, the angiographic images or duplex
ultrasonographic images should be assessed by
appropriate core laboratories and made available
to the clinical endpoints committee for review
upon request.
SHORT- AND LONG-TERM SURROGATE
ENDPOINTS FOR PROCEDURAL SUCCESS
USING IMAGING AND PHYSIOLOGICAL
MEASURES
Many imaging and physiologic surrogate endpoints
are used for both long- and short-term efﬁcacy anduccess Using Imaging and Physiologic Measures
Time Point of Evaluation
3 Months 6 Months 12 Months Ref. #
ntermittent Claudication
I or TBI $0.10 from
cedure value
Resting ABI or TBI $0.10
from pre-procedure value
Resting ABI or TBI $0.10 from
pre-procedure value
(7,29)
ollow up deﬁned as
in ABI or TBI by
eturn to pre-procedure
(29)
eter stenosis as deﬁned
systolic velocity index
f intrastenotic peak
velocity to pre-stenotic
) <2.4
#50% diameter stenosis as
deﬁned by peak systolic
velocity index (ratio of
intrastenotic peak systolic
velocity to pre-stenotic
velocity) <2.4
#50% diameter stenosis as
deﬁned by peak systolic
velocity index (ratio of
intrastenotic peak systolic
velocity to pre-stenotic
velocity) <2.4
(7)
eter stenosis or
area stenosis
#50% diameter stenosis
or #70% area stenosis
#50% diameter stenosis or
#70% area stenosis
(1,7)
Critical Limb Ischemia
m Hg (Rutherford 4)
m Hg (Rutherford 5–6)
>70 mm Hg (Rutherford 4)
>50 mm Hg (Rutherford 5–6)
>70 mm Hg (Rutherford 4)
>50 mm Hg (Rutherford 5–6)
(7,24)
diameter stenosis as
ﬁned by peak systolic
locity index (ratio of
rastenotic peak systolic
locity to pre-stenotic
locity) <2.4
#50% diameter stenosis as
deﬁned by peak systolic
velocity index (ratio of
intrastenotic peak systolic
velocity to pre-stenotic
velocity) <2.4
#50% diameter stenosis as
deﬁned by peak systolic
velocity index (ratio of
intrastenotic peak systolic
velocity to pre-stenotic
velocity) <2.4
(7)
diameter stenosis or
0% area stenosis
#50% diameter stenosis
or #70% area stenosis
#50% diameter stenosis
or #70% area stenosis
(1,7)
analyses of improvements in ABI. †The PARC group felt that the Duplex ultrasound is difﬁcult to reliably obtain in
r absence of total occlusion of below knee vessels. ‡Toe pressure and toe-brachial index should be used only in the
I patients as a guide for a threshold level to maintain adequate perfusion, applies to patients treated with either
in follow-up, as the shorter-term goals of wound healing may have been achieved. The PARC group suggests these
pre-speciﬁed reporting window to ensure all possible data and relevant ﬁndings are captured.
onance; TBI ¼ toe-brachial index; other abbreviations as in Table 2.
TABLE 6 PARC Func
Walking/functional
capacity deﬁnitions
Quality of life
(recommended
assessment tools)
Clinical assessments
Amputation
deﬁnitions
Clinical assessment
Abbreviations as in Tables
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938safety assessment in therapies aimed at patients
with LE-PAD. We focused our evaluation and deﬁ-
nitions on 3 central elements: timing of evaluation,
method of evaluation, and the patient’s clinical
presentation as intermittent claudication (or other
exertional symptoms typical of PAD) versus CLI.
The timing for evaluation was deﬁned as subacute
(from in hospital/within 72 h [whichever comes
ﬁrst] to 30 days post-index procedure) to 3, 6, and
12 months. These time frames were chosen to
match stages of interventional site healing and
device behavior, and are also consistent with
clinically meaningful and common time points of
contact with PAD patients following interventions.
Multiple modalities were included from physiolog-
ical pressure measurements, to duplex ultrasonog-
raphy, and to advanced imaging with computed
tomography and cardiac magnetic resonance imag-
ing (Table 5).tional/Clinical Outcome Deﬁnitions for Patients With Intermittent Claudi
Intermittent Claudication
Peak walking time(s) Claudication onset time(s)
Assessed using a graded treadmill
protocol that records the longest
time of exercise limited by maximally
tolerated claudication pain.
Assessed using a graded tr
that records the time d
the onset of claudicatio
clinically relevant endp
be responsive to treatm
Walking Impairment Questionnaire Peripheral Artery Question
A validated disease-speciﬁc assessment
of patient-reported outcomes that
quantiﬁes the patient’s ability to walk
a deﬁned distance, speed, and stairs.
A disease-speciﬁc health s
questionnaire that qua
patient’s physical limita
symptoms, social funct
satisfaction, and qualit
Change in symptom classiﬁcation Clinical failure
Report the change in symptom
classiﬁcation on the basis of
PARC classiﬁcation
Need for major repeat reva
(repeat endovascular in
thrombolysis, open byp
revision of existing byp
extremity amputation.
Critical Limb Ischemia
Lower extremity amputation Major amputation
Any procedure that results in the removal
of bone and tissue from the lower
extremity.
Any procedure that results
amputation at the level
above;
 Below knee amputatio
affecting the tibia at a
the knee and above th
 Above knee amputatio
above the knee, affect
at any level.
Major adverse limb events Wound healing
Above-ankle amputation of the index limb
or major repeat revascularization (new
bypass graft, jump/interposition graft
revision, or thrombectomy/
thrombolysis).
Complete epithelialization o
wound of target limb p
least 14 days.
2 and 5.CLINICAL OUTCOMES AND
ENDPOINT DEFINITIONS
Deﬁnitions for clinical outcomes in patients with LE-
PAD constitute 1 of the most complex areas for
consensus, in part due to the relevance of any
endpoint in the setting of such a heterogeneous
range of clinical syndromes. The PARC consensus
thus dichotomized patient-level endpoints on the
basis of general presentation, for example, inter-
mittent claudication/other exertional limb symp-
toms versus CLI. The endpoints for intermittent
claudication are on the basis of functional
improvement. Walking time and/or functional deﬁ-
nitions and quality-of-life deﬁnitions are presented
in Table 6. Speciﬁcally, the deﬁnition of peak
walking time on a treadmill is provided, and this
measure was felt to integrate all of the factors that
might limit an LE-PAD patient’s peak exercisecation and Critical Limb Ischemia
Ref. #
6-min walk test (feet/min)
eadmill protocol
uring exercise at
n pain. Deﬁnes a
oint, and may
ent effect.
Assessed on an unobstructed course
of 50 or 100 feet. Measures the
maximal distance walked after 6
min, regardless of whether or not
the patient stops to rest (rest
periods are acceptable).
(1,9,15)
naire (30,31)
tatus
ntiﬁes the
tions,
ion, treatment
y of life.
(9,32)
scularization
tervention,
ass, open
ass) or lower
Minor amputation (8,9,32,33)
in an
of the ankle or
n—amputation
ny point below
e ankle;
n—amputation
ing the femur
Any procedure that results in an
amputation below the ankle,
including the foot or toe(s).
Ischemic pain relief (7,8,24)
f an ischemic
ersistent for at
Improvement in (or relief of)
pain of target limb for at
least 2 weeks using visual
analogue scale.
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939performance. Treadmill testing should use stan-
dardized protocols to ensure reproducible results.
The PARC consortium did not endorse a speciﬁc
treadmill protocol. The 6-min walk distance (utilized
as a primary outcome in heart failure and pulmo-
nary hypertension studies and validated in the PAD
population) is also deﬁned on the basis of the dis-
tance walked on an unobstructed course of 50 or 100
feet (15 or 30 m). The 6-min walk test measures theCENTRAL ILLUSTRATION PARC-PAD Deﬁnitions: Consens
Lower Extremity Peripheral Artery Disease: The PARC
Food and Drug Administration,
Department of Health and Human Services
Data elements for PAD
with Lower Extremity Per
The Peripheral Academic Re
AHA/ACC Data Standards 
Document 2012
Patient Fe
and Clinical 
Clinical
Patel, M.R. et al. J Am Coll Cardiol. 2015; 65(9):931–41.
The Peripheral Academic Research Consortium (PARC) included input fr
and Medical Devices Agency to develop consensus deﬁnitions. Patient f
health records (EHRs) used in peripheral artery disease (PAD) registries
PAD in the 2012 American Heart Association/American College of Cardi
clinical care data, data elements, and PAD registries all are used in clinimaximal distance walked after 6 min, regardless of
whether the patient stops to rest or not; thus, this
test can be used to evaluate patients with severe
claudication, ischemic rest pain, or limited tissue
loss. Like all of the functional measures deﬁned, this
endpoint was felt to be clinically meaningful and
pragmatically useful, as it both characterizes a pa-
tient’s limitation at baseline and the response to
treatment.us Deﬁnitions for Evaluation of Patients With
PMDA,
Pharmaceuticals and Medical Devices Agency, Japan
ipheral Artery Disease:  
search Consortium (PARC)
PAD Registries
atures 
Care Data
 Trials
EHR
Medical 
Records
om both the Food and Drug Administration and the Pharmaceuticals
eatures and clinical care data will be entered into patients’ electronic
for clinical trials, and were on the basis of the data elements for
ology (AHA/ACC) data standards document (9). Patient features and
cal trials.
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940For patients with CLI, deﬁnitions were agreed upon
for major and minor lower extremity amputation,
wound healing, ischemic pain, and major adverse limb
events (Table 6). Major amputation was deﬁned as:
 Any procedure that results in an amputation at the
level of the ankle or above;
 Below-knee amputation—amputation affecting the
tibia at any point below the knee and above the
ankle; or
 Above-knee amputation—amputation above the
knee, affecting the femur at any level.
Major adverse limb events were deﬁned as an
above-ankle amputation of the index limb or major
repeat revascularization of the target limb (new bypass
graft, jump/interposition graft revision, repeat endo-
vascular therapy, or thrombectomy/thrombolysis).
The PARC major adverse limb event (MALE) deﬁnition
is a modiﬁcation of the Society for Vascular Surgery
deﬁnition to include all repeat open and endovascular
interventions in the target limb. After discussion, 30
days was empirically chosen as a reasonable and
objective time point to assess the early progress of
wound healing. Early wound healing was deﬁned as
complete epithelialization of an ischemicwound of the
target limb that stayed closed for at least 2 weeks,
evaluated at 30 days. Other time points may also be
appropriate and would be acceptable to the FDA for a
study designed to support a marketing application.
Hemodynamic measurements were also provided for
guidance in CLI. Taken together, the outcome deﬁni-
tions provided for both IC and CLI patients should
provide options and standard methods for evaluating
a broad range of both therapies and patients.
ADOPTION OF PARC DEFINITIONS IN CLINICAL
RESEARCH. The PARC consortium recommends
consistent application of these consensus deﬁnitions
in ongoing and future clinical trials and registries to
better and more consistently inform evaluations of
both new therapies and technologies and to support
continued improvement in correlations between in-
terventions, surrogate mechanistic measures, andclinical outcomes. The consistent use of these deﬁni-
tions support both more efﬁcient regulatory approval
of new devices and the post-market development of
best practice guidelines by professional society con-
sortia. In an effort to support adoption of these deﬁ-
nitions, the PARC group will be working with the
standards development community to accelerate
electronic data capture of these elements in national
registries and electronic health records.
CONCLUSIONS
The PARC initiative has developed a series of prag-
matic consensus deﬁnitions that include the clinical
presentation, anatomic depiction, interventional out-
comes, surrogate imaging and physiological follow-
up, and clinical outcomes of patients with LE-PAD.
Consistent application of these deﬁnitions in clinical
trials evaluating novel revascularization technologies
will result in more efﬁcient regulatory evaluation and
best practice guidelines in this rapidly moving ﬁeld
(Central Illustration). Consistent with the ARC charter,
this process and the deﬁnitions provided rely heavily
on consensus and integration of previously developed
professional society deﬁnitions, with adoption and
adaptation to optimize utility for key clinical trial
processes, such as independent adjudication, core
laboratories, and safety monitoring. As with all ARC
initiatives, the process was transparent, was inclusive
of stakeholders, and maintained a collaborative focus
on LE-PAD. The central priority was the recognition
that application of consistent deﬁnitions across clin-
ical trials of novel devices, drugs, or biologics is far
more informative for the accrual of knowledge about
optimal therapy and clinical outcomes than are at-
tempts to create novel, “perfect,” but varying deﬁni-
tions for every individual study.
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